Key Market Indicators
Sales of diabetes medicines in Latvia are expected to reach $39 million by 2026, up from $34 million in 2021. On average, the market has grown by 2.5% each year since 2006, with Latvia ranking 22nd in 2021. Slovenia was ahead at $34 million, while Canada, Spain and Italy followed in second, third and fourth place respectively. Latvian imports of insulin are forecast to decline slightly, to $10.6 million by 2026 from $11 million in 2021. Since 1999, the demand for insulin in the country has decreased by 9.1% each year. Exports of insulin from Latvia, meanwhile, are projected to reach $22.9 million by 2026, up from $18.4 million in 2021. Since 1999, the supply of insulin in the country has risen by 5.9% each year, with Latvia ranking 15th in 2021. Panama overtook Latvia with exports of $18.4 million, while France, Italy and China followed in second, third and fourth place respectively.
